- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04955847
Efficacy and Safety of Oral Misoprostol 25 μg vs. Vaginal Dinoprostone in Induction of Labor at Term (MISODINO)
Labor induction is a common medical technique. There is no consensus on which technique is better than the others. Misoprostol is an analogue of Prostaglandin E1 previously used off-label in labor induction. Its low cost, room-temperature storage, and diverse route options have made it an alternative to PGE2 in labor induction. As of 2018, oral misoprostol 25 μg tablet was licensed for labor induction.
Very few studies have been performed on oral misoprostol 25 μg and none compared it with the PGE2s mostly used in induction on unfavorable cervix at term.
The investigators compared the safety and the efficacy between the oral misoprostol 25 μg Angusta® used since 20/02/2020 and the vaginal dinoprostone previously used in gel or diffuser over two consecutive periods from 01/01/2019 to 19/02/2020 for the dinoprostone and from 20/02/2020 to 07/04/2021 for the misoprostol.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Fabrice Sergent, Pr
- Phone Number: 03 22 08 74 00.
- Email: sergent.fabrice@chu-amiens.fr
Study Locations
-
-
-
Amiens, France
- Recruiting
- CHU Amiens Picardie
-
Contact:
- Fabrice Sergent, Pr
- Phone Number: 03 22 08 74 00
- Email: sergent.fabrice@chu-amiens.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age of patient> 18 years
- patients requiring induction of labor with a singleton pregnancy at term, a gestational age greater than 37 weeks of amenorrhea, with a fetus in cephalic presentation and an unfavorable cervix (Bishop score less than six).
Exclusion Criteria:
- intrauterine fetal death,
- preterm pregnancy,
- scarred uterus
- contraindications to vaginal delivery.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
PGE2
In period 1, the service protocol for induction at term on an unfavorable cervix indicated the use of a PGE2.
In nulliparous women, Propess® was introduced intra-vaginally for 24 hours or until regular painful uterine contractions occurred.
In the case of a multiparous woman, Prostine® gel, one or two mg depending on the cervical conditions at the time of induction, was introduced intravaginally and the cervix was reassessed after six hours.
If the cervix remained unfavorable and the kinetics of the contractions were not optimal, a new dose of Prostine® one or two mg was administered to the patient.
|
misoprostol
In period 2, patients who were induced with an unfavorable cervix at term were induced with misoprostol.
Regardless of parity, the patient received oral misoprostol 25 μg, one tablet orally every two hours until a maximum of eight tablets per day, or 200 µg, was reached, with cessation of the tablets when painful, regular contractions were obtained.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variation of vaginal deliveries within 24hours patient number in both groups
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variation of Cesarean section patient number in both groups
Time Frame: 24 hours
|
24 hours
|
Variation of indications for cesarean section in both groups
Time Frame: 24 hours
|
24 hours
|
Variation of uterine contractility abnormalities in both groups
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PI2021_843_0070
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cesarean Section
-
Assiut UniversityNot yet recruitingCesarean Section Complications | Cesarean Section Niche
-
Recep Tayyip Erdogan University Training and Research...CompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Ataturk UniversityUnknownCesarean Section Complications | Cesarean Section; Complications, Wound, Dehiscence | Cesarean Section, Repeated | Cesarean, Uterine Scar Thickness | Cesarean, Residual Myometrial ThicknessTurkey
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Odense University HospitalHvidovre University Hospital; Smith & Nephew, Inc.; University of Southern Denmark and other collaboratorsCompletedSurgical Wound Infection | Cesarean Section; Dehiscence | Complications; Cesarean Section | Infection; Cesarean Section | Complications; Cesarean Section, Wound, Dehiscence | Wound; Rupture, Surgery, Cesarean SectionDenmark
-
Virginia Commonwealth UniversityRecruitingCesarean SectionUnited States
-
University Tunis El ManarCompleted
-
Federico II UniversityCompletedCesarean SectionItaly
-
Virginia Commonwealth UniversityCompletedCesarean SectionUnited States
-
University of CalgaryCompleted